pubmed-article:12576231 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:12576231 | lifeskim:mentions | umls-concept:C0026769 | lld:lifeskim |
pubmed-article:12576231 | lifeskim:mentions | umls-concept:C0028944 | lld:lifeskim |
pubmed-article:12576231 | lifeskim:mentions | umls-concept:C0017968 | lld:lifeskim |
pubmed-article:12576231 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
pubmed-article:12576231 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
pubmed-article:12576231 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
pubmed-article:12576231 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
pubmed-article:12576231 | pubmed:issue | 1-2 | lld:pubmed |
pubmed-article:12576231 | pubmed:dateCreated | 2003-2-10 | lld:pubmed |
pubmed-article:12576231 | pubmed:abstractText | Humoral auto-immunity to the myelin oligodendrocyte glycoprotein (MOG) is likely involved in the pathogenesis of multiple sclerosis (MS). In 44 MS patients and 30 controls, Ig-producing B cells were identified by their isotype and as MOG-specific spot-forming cells (SFC). Peripheral anti-MOG antibodies were assayed in ELISA as well as anti-butyrophilin antibodies to investigate for molecular mimicry. MS patients had significantly higher levels of IgA- and MOG-SFC than controls, as well as significantly higher antibody responses to MOG and butyrophilin. These data provide added support for the implication of anti-MOG humoral immunity in the pathophysiology of MS, and suggest a balance of systemic (anti-self) and mucosal (environment-modulated) immune reactions in an attempt at regulating the pathogenic specific immune response. | lld:pubmed |
pubmed-article:12576231 | pubmed:language | eng | lld:pubmed |
pubmed-article:12576231 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12576231 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:12576231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12576231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12576231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12576231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12576231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12576231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12576231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12576231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12576231 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:12576231 | pubmed:month | Feb | lld:pubmed |
pubmed-article:12576231 | pubmed:issn | 0165-5728 | lld:pubmed |
pubmed-article:12576231 | pubmed:author | pubmed-author:BénéM CMC | lld:pubmed |
pubmed-article:12576231 | pubmed:author | pubmed-author:FaureG CGC | lld:pubmed |
pubmed-article:12576231 | pubmed:author | pubmed-author:Kolopp-SardaM... | lld:pubmed |
pubmed-article:12576231 | pubmed:author | pubmed-author:Kennel De... | lld:pubmed |
pubmed-article:12576231 | pubmed:author | pubmed-author:De BouwerieMM | lld:pubmed |
pubmed-article:12576231 | pubmed:author | pubmed-author:BernardC C... | lld:pubmed |
pubmed-article:12576231 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:12576231 | pubmed:volume | 135 | lld:pubmed |
pubmed-article:12576231 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:12576231 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:12576231 | pubmed:pagination | 117-25 | lld:pubmed |
pubmed-article:12576231 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
pubmed-article:12576231 | pubmed:meshHeading | pubmed-meshheading:12576231... | lld:pubmed |
pubmed-article:12576231 | pubmed:meshHeading | pubmed-meshheading:12576231... | lld:pubmed |
pubmed-article:12576231 | pubmed:meshHeading | pubmed-meshheading:12576231... | lld:pubmed |
pubmed-article:12576231 | pubmed:meshHeading | pubmed-meshheading:12576231... | lld:pubmed |
pubmed-article:12576231 | pubmed:meshHeading | pubmed-meshheading:12576231... | lld:pubmed |
pubmed-article:12576231 | pubmed:meshHeading | pubmed-meshheading:12576231... | lld:pubmed |
pubmed-article:12576231 | pubmed:meshHeading | pubmed-meshheading:12576231... | lld:pubmed |
pubmed-article:12576231 | pubmed:meshHeading | pubmed-meshheading:12576231... | lld:pubmed |
pubmed-article:12576231 | pubmed:meshHeading | pubmed-meshheading:12576231... | lld:pubmed |
pubmed-article:12576231 | pubmed:meshHeading | pubmed-meshheading:12576231... | lld:pubmed |
pubmed-article:12576231 | pubmed:meshHeading | pubmed-meshheading:12576231... | lld:pubmed |
pubmed-article:12576231 | pubmed:meshHeading | pubmed-meshheading:12576231... | lld:pubmed |
pubmed-article:12576231 | pubmed:meshHeading | pubmed-meshheading:12576231... | lld:pubmed |
pubmed-article:12576231 | pubmed:meshHeading | pubmed-meshheading:12576231... | lld:pubmed |
pubmed-article:12576231 | pubmed:meshHeading | pubmed-meshheading:12576231... | lld:pubmed |
pubmed-article:12576231 | pubmed:meshHeading | pubmed-meshheading:12576231... | lld:pubmed |
pubmed-article:12576231 | pubmed:meshHeading | pubmed-meshheading:12576231... | lld:pubmed |
pubmed-article:12576231 | pubmed:meshHeading | pubmed-meshheading:12576231... | lld:pubmed |
pubmed-article:12576231 | pubmed:year | 2003 | lld:pubmed |
pubmed-article:12576231 | pubmed:articleTitle | Anti-myelin oligodendrocyte glycoprotein B-cell responses in multiple sclerosis. | lld:pubmed |
pubmed-article:12576231 | pubmed:affiliation | Laboratoire d'Immunologie du CHU, Faculté de Médecine, BP 184, 54500 Vandoeuvre les, 54000, Nancy, France. | lld:pubmed |
pubmed-article:12576231 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:12576231 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12576231 | lld:pubmed |